Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13Monovich, L.G., Tommasi, R.A., Fujimoto, R.A., Blancuzzi, V., Clark, K., Cornell, W.D., Doti, R., Doughty, J., Fang, J., Farley, D., Fitt, J., Ganu, V., Goldberg, R., Goldstein, R., Lavoie, S., Kulathila, R., Macchia, W., Parker, D.T., Melton, R., O'Byrne, E., Pastor, G., Pellas, T., Quadros, E., Reel, N., Roland, D.M., Sakane, Y., Singh, H., Skiles, J., Somers, J., Toscano, K., Wigg, A., Zhou, S., Zhu, L., Shieh, W.C., Xue, S., McQuire, L.W.
(2009) J Med Chem 52: 3523-3538
- PubMed: 19422229
- DOI: 10.1021/jm801394m
- Primary Citation of Related Structures:
- PubMed Abstract:
The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis ...
The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would therefore be a novel disease modifying therapy for the treatment of arthritis. Our efforts have resulted in the discovery of a series of carboxylic acid inhibitors of MMP-13 that do not significantly inhibit the related MMP-1 (collagenase-1) or tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE). It has previously been suggested (but not proven) that inhibition of the latter two enzymes could lead to side effects. A promising carboxylic acid lead 9 was identified and a convergent synthesis developed. This paper describes the optimization of 9 and the identification of a compound 24f for further development. Compound 24f is a subnanomolar inhibitor of MMP-13 (IC(50) value 0.5 nM and K(i) of 0.19 nM) having no activity against MMP-1 or TACE (IC(50) of >10000 nM). Furthermore, in a rat model of MMP-13-induced cartilage degradation, 24f significantly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p < 0.05) and at 10 mg/kg (40% inhibition, p < 0.05).
Arthritis and Bone Metabolism Research, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.